The Inhibition of the Degrading Enzyme Fatty Acid Amide Hydrolase Alters the Activity of the Cone System in the Vervet Monkey Retina.
FAAH
URB597
cone pathway
endocannabinoids
flicker electroretinogram
retina
vervet monkeys
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
27
09
2021
revised:
20
10
2021
accepted:
25
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Recent studies using full-field electroretinography (ffERG) that triggers a non-specific mass response generated by several retinal sources have attributed an important role for cannabinoid receptors in mediating vision in primates. Specific cone-mediated responses evoked through the photopic flicker ERG appear to be a better way to validate the assumption that endogenous cannabinoids modulate the cone pathway, since FAAH is mainly expressed in the vervet monkey cone photoreceptors. The aim of this study is two-fold: (1) to use the photopic flicker ERG to target the cone pathway specifically, and (2) use URB597 as a selective inhibitor of the endocannabinoid degrading enzyme Fatty Acid Amide Hydrolase (FAAH) to enhance the levels of fatty acid amides, particularly anandamide. We recorded ERGs under four different flicker frequencies (15, 20, 25, and 30 Hz) in light-adapted conditions after intravitreal injections of URB597. Our results show that intravitreal injections of URB597, compared to the vehicle DMSO, increased significantly ffERG amplitudes at 30 Hz, a frequency that solely recruits cone activity. However, at 15 Hz, a frequency that activates both rods and cones, no significant difference was found in the ERG response amplitude. Additionally, we found no differences in implicit times after URB597 injections compared to DMSO vehicle. These results support the role of molecules degraded by FAAH in cone-mediated vision in non-human primates.
Identifiants
pubmed: 34827417
pii: brainsci11111418
doi: 10.3390/brainsci11111418
pmc: PMC8615683
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Natural Sciences and Engineering Research Council
ID : 6362-2017: M.P.; RGPIN- 2020-05739: J.-F.B
Organisme : CIHR
ID : 163014-2019: M.P. and J.-F.B., PJT-156029: J.-F.B.
Pays : Canada
Références
Neural Plast. 2016;2016:2916732
pubmed: 26881099
Nature. 1996 Nov 7;384(6604):83-7
pubmed: 8900284
J Psychiatr Res. 2018 Aug;103:75-82
pubmed: 29783078
Exp Eye Res. 2020 Dec;201:108266
pubmed: 32979397
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):305-12
pubmed: 11133883
Nat Rev Neurosci. 2003 Nov;4(11):873-84
pubmed: 14595399
Neuroscience. 2015 Aug 20;301:563-75
pubmed: 25795598
Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8079-90
pubmed: 24255040
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
pubmed: 7575630
Neural Plast. 2016;2016:9247057
pubmed: 26839718
Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):413-8
pubmed: 17011761
Biochem Pharmacol. 1993 Sep 1;46(5):791-6
pubmed: 8373432
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2442-8
pubmed: 10476817
Doc Ophthalmol. 1986 Mar 31;62(3):231-45
pubmed: 3486101
J Comp Neurol. 2011 May 1;519(7):1258-80
pubmed: 21452196
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):2997-3004
pubmed: 17591864
Curr Neuropharmacol. 2018;16(7):959-970
pubmed: 28738764
Prog Retin Eye Res. 2008 Sep;27(5):501-26
pubmed: 18725316
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:264
pubmed: 24732440
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2500-7
pubmed: 12091456
J Med Chem. 2004 Oct 7;47(21):4998-5008
pubmed: 15456244
Surv Ophthalmol. 2016 Mar-Apr;61(2):187-96
pubmed: 26074354
Appl Opt. 1991 Jun 1;30(16):2106-12
pubmed: 20700185
PLoS One. 2013 Nov 14;8(11):e81080
pubmed: 24244730
Nat Rev Neurol. 2020 Jan;16(1):9-29
pubmed: 31831863
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14565-70
pubmed: 10588745
Neuroscience. 2011 Nov 10;195:145-65
pubmed: 21867744
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1693-8
pubmed: 8675413
J Comp Neurol. 2013 Aug 1;521(11):2399-415
pubmed: 23630038
Nat Rev Drug Discov. 2008 May;7(5):438-55
pubmed: 18446159
J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):253-65
pubmed: 26565550
PLoS One. 2014 Oct 31;9(10):e111569
pubmed: 25360686
J Vis. 2009 Mar 13;9(3):9.1-12
pubmed: 19757948
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
pubmed: 7605349
Neuropharmacology. 2018 Oct;141:21-31
pubmed: 30121200
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Vision Res. 2006 Sep;46(17):2773-85
pubmed: 16494917
Eur Neuropsychopharmacol. 2015 Jan;25(1):100-12
pubmed: 25482685
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704
pubmed: 18263732
Sci Rep. 2020 Jul 21;10(1):12116
pubmed: 32694518
Neuropharmacology. 2013 Sep;72:116-25
pubmed: 23643752
Neural Plast. 2016;2016:3127658
pubmed: 26977322
Acta Physiol Scand. 1957 Jun 8;39(2-3):158-66
pubmed: 13444030
Sci Rep. 2020 Sep 25;10(1):15819
pubmed: 32978469
Vis Neurosci. 2016 Jan;33:E006
pubmed: 27485069
Neural Plast. 2016;2016:1253245
pubmed: 27069692
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4328-35
pubmed: 16249515
Neuroscience. 2012 Jan 27;202:117-30
pubmed: 22142900